What newer pharmacologic agents are recommended for treating insomnia in adults, including appropriate dosing, titration, safety considerations for older adults, and contraindications?

New Sleep Medications for Insomnia

Among newer pharmacologic agents for insomnia, suvorexant (a dual orexin receptor antagonist) represents the most novel mechanism and is recommended specifically for sleep maintenance insomnia at doses of 10-20 mg, while eszopiclone (2-3 mg) and zolpidem (10 mg) remain effective options for both sleep onset and maintenance. 1

Recommended Newer Agents by Insomnia Type

For Sleep Maintenance Insomnia (Middle-of-Night/Early Morning Awakening)

Suvorexant is the newest class of medication—an orexin receptor antagonist that works by blocking wakefulness signals rather than inducing sedation 1. This represents a fundamentally different mechanism from older hypnotics:

• Dosing: 10 mg, 15/20 mg, or 20 mg at bedtime 1
• Mechanism advantage: Inhibits wake-promoting orexin signaling rather than forcing sedation
• Safety profile: No evidence of rebound insomnia, withdrawal, or abuse potential 2
• Older adults: Better tolerated than benzodiazepines and Z-drugs, with lower fall risk 3

Low-dose doxepin (3-6 mg) is another option specifically for sleep maintenance 1. This is a tricyclic antidepressant used at doses far below antidepressant levels, acting primarily as a histamine antagonist. It's particularly useful in older adults 4.

For Sleep Onset Insomnia (Difficulty Falling Asleep)

Ramelteon (8 mg) is a melatonin receptor agonist that promotes sleep initiation through circadian mechanisms 1. Unlike traditional hypnotics:

• No controlled substance classification
• No abuse potential
• Particularly appropriate for older adults (≥55 years) 5
• Works by mimicking natural melatonin signaling

Zaleplon (10 mg) is an ultra-short-acting Z-drug useful for sleep onset, with minimal next-day effects due to its brief half-life 1.

For Both Sleep Onset and Maintenance

Eszopiclone (2-3 mg) and zolpidem (10 mg) remain effective options, though they are not truly "new" 1. The evidence shows:

• Small to moderate effect sizes for sleep outcomes
• Low-to-moderate quality evidence supporting use
• FDA warnings about next-day impairment, especially in women and older adults
• Maximum 28-day prescription duration recommended 5

Emerging Agents (Not Yet Widely Available)

Daridorexant and lemborexant are newer dual orexin receptor antagonists (DORAs) showing promise 2:

• Daridorexant has an ideal 8-hour half-life
• Demonstrated 12-month efficacy without tolerance
• Similar safety profile to suvorexant
• May become preferred options as availability increases

Critical Safety Considerations for Older Adults

The choice of agent must account for age-related risks:

Avoid in older adults:

• Benzodiazepines (high fall risk, cognitive impairment, mortality concerns) 3
• Diphenhydramine and antihistamines (anticholinergic burden, next-day sedation) 1, 5
• Long-acting benzodiazepines (prolonged sedation, accumulation)

Preferred in older adults:

• Suvorexant or other DORAs (lowest fall/injury risk) 4, 3
• Low-dose doxepin 3-6 mg (well-tolerated at these doses) 4
• Ramelteon (no sedation-related adverse effects) 4
• Melatonin extended-release (for those ≥55 years) 5

Dose adjustments required:

• FDA recommends lower doses for women and older adults across all Z-drugs
• Zolpidem: 5 mg (not 10 mg) in women and older adults
• Eszopiclone: Start 1 mg in older adults

Contraindications and Warnings

Absolute contraindications:

• Suvorexant: Narcolepsy (worsens cataplexy)
• All sedative-hypnotics: Severe respiratory impairment, sleep apnea (relative)
• Ramelteon: Severe hepatic impairment

FDA black box warnings apply to all sedative-hypnotics:

• Complex sleep behaviors ("sleep driving," sleep-eating)
• Next-day driving impairment
• Risk of falls and fractures (especially older adults)
• Potential for cognitive/behavioral changes
• Observational data suggest associations with dementia and serious injury 6, 7

Medications to Avoid

The AASM explicitly recommends against these commonly used agents 1:

• Trazodone (insufficient efficacy data despite widespread off-label use)
• Melatonin (over-the-counter formulations—inconsistent quality and dosing)
• Diphenhydramine (anticholinergic effects, tolerance)
• Tiagabine (not effective, should not be used)
• Valerian, tryptophan (insufficient evidence)

Practical Prescribing Algorithm

Step 1: Determine insomnia pattern

• Sleep onset only → Ramelteon 8 mg or zaleplon 10 mg
• Sleep maintenance only → Suvorexant 10-20 mg or doxepin 3-6 mg
• Both onset and maintenance → Eszopiclone 2-3 mg or suvorexant

Step 2: Consider patient factors

• Age ≥65 years → Prioritize suvorexant, low-dose doxepin, or ramelteon
• Women → Use FDA-recommended lower doses of Z-drugs
• Hepatic impairment → Avoid ramelteon; reduce doses of others
• Depression comorbidity → Low-dose doxepin may address both

Step 3: Set expectations

• Pharmacotherapy should be short-term (4-5 weeks maximum for Z-drugs) 7
• Cognitive behavioral therapy for insomnia (CBT-I) remains first-line; medications are adjunctive 7
• Plan for medication taper and discontinuation

Step 4: Monitor closely

• Follow-up every few weeks initially 8
• Assess effectiveness, adverse effects, and need for continuation
• Screen for complex sleep behaviors, next-day impairment, falls

Key Strength of Evidence Caveat

All pharmacologic recommendations carry WEAK strength under GRADE methodology 1. This reflects:

• Small effect sizes (typically 15-30 minutes improvement in sleep latency)
• Industry funding bias in most trials
• Limited long-term efficacy data
• Heterogeneity across studies

The weakness of recommendations does not mean ineffectiveness—it reflects the quality and certainty of available evidence. In clinical practice, these medications do provide meaningful benefit for many patients when used appropriately and short-term.